Study of Tumor Samples From Patients With Ewing Sarcoma
Recruitment status was Active, not recruiting
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at tumor samples from patients with Ewing sarcoma.
Genetic: fluorescence in situ hybridization
Genetic: mutation analysis
Genetic: nucleic acid sequencing
Genetic: polymerase chain reaction
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
|Official Title:||Prognostic Value of p53 and/or p16 Alterations in Ewing Sarcoma|
- Event-free survival [ Designated as safety issue: No ]
- Incidence of p53 mutations [ Designated as safety issue: No ]
- Incidence of p16 loss or deletion [ Designated as safety issue: No ]
|Study Start Date:||September 2008|
|Estimated Primary Completion Date:||April 2010 (Final data collection date for primary outcome measure)|
- Determine if mutation of p53, and/or deletion of the p16 locus, have prognostic value in patients with Ewing sarcoma.
- Estimate the incidence of p53 mutation in Ewing sarcoma samples collected from COG studies.
- Estimate the incidence of p16 deletions in Ewing sarcoma samples collected from COG studies.
- Prepare and archive amplified genomic DNA from Ewing sarcoma samples collected from COG studies for future biologic analysis.
OUTLINE: This is a multicenter study.
Previously archived tumor samples are analyzed for p53 mutations and p16 deletion by immunohistochemistry, FISH, PCR, and DNA sequencing.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00898053
|Study Chair:||Stephen Lessnick, MD, PhD||University of Utah|